Moscow:
Russia’s sovereign wealth fund and Indian pharmaceutical corporation Hetero have agreed to generate more than one hundred million doses per year in India of the Sputnik V vaccine against COVID-19, according to a statement on the Sputnik V Twitter account on Friday.
Hetero and the Russian Direct Investment Fund (RDIF), which has been backing the vaccine and marketing and advertising it globally, strategy to start off production of Sputnik V in India at the starting of 2021, the statement mentioned.
Phase II-III trials are ongoing in India, the statement mentioned. Drugmaker Dr Reddy’s Laboratories Ltd has mentioned it expects late-stage trials to be completed by as early as March 2021.
()